Loading...
Savara Q1 2025 Earnings Report
Savara reported a net loss of $26.64 million in Q1 2025, an increase from the net loss of $20.35 million in Q1 2024, primarily due to increased operating expenses.
Key Takeaways
Savara Inc. experienced a larger net loss in the first quarter of 2025 compared to the same period last year, driven by significant increases in research and development and general and administrative expenses. The company continues to focus on the development of its product candidate, MOLBREEVI, and maintains a strong cash position to fund its planned activities.
Net loss increased to $26.64 million in Q1 2025 from $20.35 million in Q1 2024.
Research and development expenses rose by 14.0% to $19.16 million, mainly due to regulatory affairs and quality assurance for MOLBREEVI.
General and administrative expenses increased by 64.1% to $9.25 million, driven by personnel costs and commercial activities.
Cash and cash equivalents, along with short-term investments, totaled $172.5 million as of March 31, 2025, providing sufficient capital for planned activities.
Savara
Savara
Forward Guidance
Savara anticipates continued significant expenses and operating losses for the next several years as it advances its primary product candidate, MOLBREEVI, through clinical development and regulatory approval. The company expects to require additional capital to fund future activities, including potential commercialization.
Positive Outlook
- Completed BLA submission to the FDA for MOLBREEVI, a significant regulatory milestone.
- Secured a new Hercules Loan Agreement for up to $200 million, providing substantial funding capacity.
- Initial advance of $30 million from the Hercules Loan Agreement used to repay prior debt and fund general corporate purposes.
- Potential for additional draws from the Hercules Loan Agreement upon achieving FDA approval and revenue milestones.
- Maintains a strong cash and short-term investments position of $172.5 million as of March 31, 2025.
Challenges Ahead
- Expects to incur significant additional expenses and operating losses for at least the next several years.
- Future funding requirements are substantial and depend on the pace and results of clinical development efforts.
- Failure to raise additional capital on favorable terms could negatively impact development and commercialization activities.
- The company has never been profitable and has incurred operating losses every year since inception.
- The cost to further develop and obtain regulatory approval for any drug is substantial.